THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS
申请人:Cravo Daniel
公开号:US20110034505A1
公开(公告)日:2011-02-10
The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim
1
, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).
[EN] CYCLIC PHOSPHATE COMPOUNDS<br/>[FR] COMPOSÉS DE PHOSPHATE CYCLIQUE
申请人:LIGAND PHARM INC
公开号:WO2020219464A1
公开(公告)日:2020-10-29
Provided herein are cyclic phosphate compounds, their preparation and their uses, such as treating liver diseases or conditions or a disease or condition in which the physiological or pathogenic pathways involve the liver.
3-AMINOIMIDAZO 1,2-A PYRIDINE DERIVATIVES HAVING AN SGLT1- AND SGLT2-INHIBITING ACTION FOR THE TREATMENT OF TYPE 1 AND TYPE 2 DIABETES
申请人:Klein Markus
公开号:US20100305142A1
公开(公告)日:2010-12-02
Novel compounds of the formula (I), in which W, T, R
1
, R
2
, R
3
, R
4
, R
5
and R
6
have the meanings indicated in Patent Claim (
1
), are suitable as antidiabetics.
The invention provides compounds of Formula (I)
as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.
[EN] POLYCYCLIC PYRIDONE COMPOUNDS AS ANTIVIRALS<br/>[FR] COMPOSÉS PYRIDONES POLYCYCLIQUES UTILES EN TANT QU'AGENTS ANTIVIRAUX
申请人:NOVARTIS AG
公开号:WO2018047109A1
公开(公告)日:2018-03-15
The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.